Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

In vitro drug susceptibility of two strains of the wildlife trypanosome, Trypanosoma copemani: A comparison with Trypanosoma cruzi.

Tytuł:
In vitro drug susceptibility of two strains of the wildlife trypanosome, Trypanosoma copemani: A comparison with Trypanosoma cruzi.
Autorzy:
Botero A; School of Veterinary and Life Sciences, Murdoch University, South Street, Murdoch, WA 6150, Australia. Electronic address: .
Keatley S; School of Veterinary and Life Sciences, Murdoch University, South Street, Murdoch, WA 6150, Australia.
Peacock C; The Marshall Center, School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, WA 6009, Australia; Telethon Kids Institute, 100 Roberts Road, Subiaco, WA 6008, Australia.
Thompson RC; School of Veterinary and Life Sciences, Murdoch University, South Street, Murdoch, WA 6150, Australia.
Źródło:
International journal for parasitology. Drugs and drug resistance [Int J Parasitol Drugs Drug Resist] 2017 Apr; Vol. 7 (1), pp. 34-41. Date of Electronic Publication: 2016 Dec 23.
Typ publikacji:
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: [Amsterdam] : Elsevier, 2011-
MeSH Terms:
Animals, Wild/*parasitology
Trypanocidal Agents/*pharmacology
Trypanosoma/*drug effects
Trypanosoma cruzi/*drug effects
Animals ; Australia ; Cell Line ; Drug Discovery ; High-Throughput Screening Assays ; Inhibitory Concentration 50 ; Melarsoprol/pharmacology ; Melarsoprol/toxicity ; Nitroimidazoles/pharmacology ; Phosphorylcholine/analogs & derivatives ; Phosphorylcholine/pharmacology ; Phosphorylcholine/toxicity ; Potoroidae/parasitology ; Pyrimidines/pharmacology ; Triazoles/pharmacology ; Trypanosoma/isolation & purification ; Trypanosoma cruzi/isolation & purification
References:
Acta Trop. 1997 Apr 15;64(3-4):145-54. (PMID: 9107362)
Bioorg Med Chem. 2013 Apr 1;21(7):1756-63. (PMID: 23462713)
Mol Biochem Parasitol. 2011 Mar;176(1):8-16. (PMID: 21073906)
PLoS One. 2008;3(11):e3602. (PMID: 18985148)
Future Med Chem. 2013 Oct;5(15):1733-52. (PMID: 24144410)
Anticancer Res. 1996 May-Jun;16(3B):1429-39. (PMID: 8694511)
Mem Inst Oswaldo Cruz. 1996 Sep-Oct;91(5):609-18. (PMID: 9137746)
Basic Clin Pharmacol Toxicol. 2005 Jan;96(1):60-5. (PMID: 15667597)
J Parasitol. 1991 Aug;77(4):624-7. (PMID: 1907654)
Biochem Pharmacol. 2001 Sep 15;62(6):765-72. (PMID: 11551522)
Expert Opin Ther Targets. 2009 Jan;13(1):105-21. (PMID: 19063710)
Antimicrob Agents Chemother. 2009 Sep;53(9):3855-9. (PMID: 19546361)
Parasitol Res. 2016 Oct;115(10 ):3699-703. (PMID: 27457482)
Biomedica. 2009 Sep;29(3):448-55. (PMID: 20436996)
Am J Trop Med Hyg. 2009 Oct;81(4):665-74. (PMID: 19815884)
J Antimicrob Chemother. 2012 Nov;67(11):2576-97. (PMID: 22833634)
J Antimicrob Chemother. 2012 May;67(5):1261-6. (PMID: 22331592)
Biochem Pharmacol. 2001 Jan 1;61(1):1-5. (PMID: 11137702)
Blood. 1997 Jul 15;90(2):562-70. (PMID: 9226155)
Curr Top Med Chem. 2011;11(16):2060-71. (PMID: 21619513)
Toxicol In Vitro. 2004 Oct;18(5):703-10. (PMID: 15251189)
J Biol Chem. 2013 Nov 1;288(44):31602-15. (PMID: 24047900)
Cancer Res. 1999 Mar 1;59(5):1041-8. (PMID: 10070961)
PLoS Med. 2006 Sep;3(9):e355. (PMID: 17002503)
J Immunol Methods. 1994 Apr 15;170(2):211-24. (PMID: 8157999)
PLoS One. 2011;6(7):e22155. (PMID: 21814568)
Int J Parasitol Drugs Drug Resist. 2015 Jun 20;5(3):117-26. (PMID: 26199860)
Antimicrob Agents Chemother. 2002 Nov;46(11):3472-7. (PMID: 12384352)
Am J Trop Med Hyg. 2011 Aug;85(2):221-4. (PMID: 21813838)
Lancet. 1992 Sep 12;340(8820):652-5. (PMID: 1355219)
Parasitol Res. 2008 Apr;102(5):1059-67. (PMID: 18224488)
PLoS Negl Trop Dis. 2013 Oct 10;7(10):e2475. (PMID: 24130910)
J Antimicrob Chemother. 1996 Dec;38(6):1041-7. (PMID: 9023651)
Acta Trop. 1997 Nov;68(2):139-47. (PMID: 9386789)
Sci Rep. 2014 Apr 16;4:4703. (PMID: 24736467)
PLoS Negl Trop Dis. 2014 Dec 04;8(12):e3259. (PMID: 25474364)
Parasite. 2013;20:39. (PMID: 24139487)
Antimicrob Agents Chemother. 2004 Sep;48(9):3268-71. (PMID: 15328083)
J Med Chem. 2013 Dec 27;56(24):10158-70. (PMID: 24304150)
Rev Inst Med Trop Sao Paulo. 1997 Sep-Oct;39(5):283-90. (PMID: 9661307)
Clin Infect Dis. 2013 Jan;56(2):195-203. (PMID: 23074318)
PLoS Negl Trop Dis. 2012 Jan;6(1):e1463. (PMID: 22272366)
Int J Parasitol Drugs Drug Resist. 2012 Mar 03;2:262-70. (PMID: 24533287)
Acta Trop. 2000 Mar 25;75(2):219-28. (PMID: 10708662)
Mem Inst Oswaldo Cruz. 2014 Jun;109(3):362-4. (PMID: 24831550)
Protist. 2016 Feb;167(1):82-92. (PMID: 26712388)
Antimicrob Agents Chemother. 2012 Jul;56(7):3864-72. (PMID: 22585212)
Mem Inst Oswaldo Cruz. 2011 Jun;106(4):475-8. (PMID: 21739037)
Int J Parasitol Parasites Wildl. 2013 Mar 29;2:77-89. (PMID: 24533319)
Parasit Vectors. 2010 Mar 10;3(1):15. (PMID: 20219092)
Antimicrob Agents Chemother. 2014;58(1):144-52. (PMID: 24145529)
Antimicrob Agents Chemother. 2013 Jan;57(1):390-5. (PMID: 23114763)
J Med Chem. 2012 May 10;55(9):4189-204. (PMID: 22536986)
Cell Mol Life Sci. 2016 Sep;73(17):3387-400. (PMID: 26973180)
PLoS One. 2012;7(9):e44640. (PMID: 22970274)
Clin Infect Dis. 2010 Nov 15;51(10):e69-75. (PMID: 20932171)
J Antimicrob Chemother. 2001 May;47(5):537-46. (PMID: 11328763)
PLoS Negl Trop Dis. 2013 Aug 15;7(8):e2367. (PMID: 23967360)
Parasitology. 2011 Jan;138(1):59-70. (PMID: 20663248)
Parasitol Res. 2006 Jul;99(2):103-7. (PMID: 16506080)
Parasitology. 2009 Jun;136(7):783-92. (PMID: 19416553)
Hum Exp Toxicol. 2006 Aug;25(8):471-9. (PMID: 16937919)
Contributed Indexing:
Keywords: High throughput screening; Lead compounds; Trypanosoma copemani; Trypanosoma cruzi; Woylie
Substance Nomenclature:
0 (Nitroimidazoles)
0 (Pyrimidines)
0 (Triazoles)
0 (Trypanocidal Agents)
107-73-3 (Phosphorylcholine)
53EY29W7EC (miltefosine)
6TK1G07BHZ (posaconazole)
YC42NRJ1ZD (benzonidazole)
ZF3786Q2E8 (Melarsoprol)
Entry Date(s):
Date Created: 20170102 Date Completed: 20171024 Latest Revision: 20181113
Update Code:
20240104
PubMed Central ID:
PMC5219620
DOI:
10.1016/j.ijpddr.2016.12.004
PMID:
28040568
Czasopismo naukowe
Trypanosomes are blood protozoan parasites that are capable of producing illness in the vertebrate host. Within Australia, several native Trypanosoma species have been described infecting wildlife. However, only Trypanosoma copemani has been associated with pathological lesions in wildlife hosts and more recently has been associated with the drastic decline of the critically endangered woylie (Bettongia penicillata). The impact that some trypanosomes have on the health of the vertebrate host has led to the development of numerous drug compounds that could inhibit the growth or kill the parasite. This study investigated and compared the in vitro susceptibility of two strains of T. copemani (G1 and G2) and one strain of Trypanosoma cruzi (10R26) against drugs that are known to show trypanocidal activity (benznidazole, posaconazole, miltefosine and melarsoprol) and against four lead compounds, two fenarimols and two pyridine derivatives (EPL-BS1937, EPL-BS2391, EPL-BS0967, and EPL-BS1246), that have been developed primarily against T.cruzi. The in vitro cytotoxicity of all drugs against L6 rat myoblast cells was also assessed. Results showed that both strains of T. copemani were more susceptible to all drugs and lead compounds than T. cruzi, with all IC50 values in the low and sub-μM range for both species. Melarsoprol and miltefosine exhibited the highest drug activity against both T. copemani and T. cruzi, but they also showed the highest toxicity in L6 cells. Interestingly, both fenarimol and pyridine derivative compounds were more active against T. copemani and T. cruzi than the reference drugs benznidazole and posaconazole. T. copemani strains exhibited differences in susceptibility to all drugs demonstrating once again considerable differences in their biological behaviour.
(Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies